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The management of perioperative medications is a tale
of progressive scientific enquiry. Although long-term
use of agents such as aspirin or statins improves clinical
outcomes, use during surgery ranges from problematic
to protective. The delicate balance between proven
long-term benefits in the nonoperative setting versus
short-term uncertainty in the perioperative setting must
be assessed using a lens that incorporates patient risk,
surgical process, and pharmacodynamic principles.
Advances in our understanding of perioperative physi-
ology, coupled with robust clinical and outcome data,
have led to new knowledge and insights regarding how
best to manage these medications. As well illustrated
by the near 180 change in the use of perioperative b-
blockers to prevent adverse cardiovascular outcomes,
these new data have led to substantial progress in sur-
gical safety and patient outcomes.
In this issue of the Journal of Hospital Medicine, 2
retrospective cohort studies add to this growing body
of evidence by examining risks associated with use of
angiotensin-converting enzyme (ACE) inhibitors in the
perioperative setting. In the first study, conducted at a
single academic medical center, Nielson and col-
leagues evaluate the association of preoperative ACE-
inhibitor use with hypotension and acute kidney
injury in patients undergoing major elective orthope-
dic surgery.1 The authors report that patients receiv-
ing ACE-inhibitors were not only more likely to
experience hypotension after induction of anesthesia
(12.2% vs 6.7%, P 5 0.005), but also were more
likely to develop postoperative acute kidney injury
(odds ratio [OR]: 2.68, 95% confidence interval [CI]:
1.25-1.99). In the second study which focused solely
on patients who were receiving preoperative ACE-
inhibitor therapy, Mudumbai and colleagues used a
national Veterans Affairs database to examine the
association between failure to resume ACE-inhibitor
treatment after surgery and outcomes at 30 days.2
The authors found that failure to resume treatment 14
days after surgery was not only common (affecting 1
in 4 patients), but was also associated with increased
30-day mortality (hazard ratio: 3.44, 95% CI: 3.30-
3.60).2 Taken together, these 2 studies shed new light
on clinical practice and policy implications for the use
of these agents in the surgical period. Both sets of
authors should be congratulated on moving the needle
forward in this enquiry.
ACE-inhibitors physiologically mediate their effects
by preventing the formation of the potent vasocon-
strictor angiotensin-II from its precursor angiotensin-I.
In doing so, they decrease arterial resistance, increase
venous capacitance, decrease glomerular filtration
pressure, and promote natriuresis. These vascular
effects have key benefits for the management of a
number of chronic diseases including hypertension,
congestive heart failure, and diabetic nephropathy.
However, these clinical alterations are often problem-
atic in the perioperative setting. For example, ACE-
inhibitors may cause vasoplegia during anesthetic
administration, commonly manifested as hypotension
during induction.3 This hemodynamic alteration has
been viewed as being so precarious, that some authors
recommend withholding ACE-inhibitors prior to
major cardiovascular procedures such as coronary
artery bypass grafting.4 Although hypotension leads to
management challenges (often increasing vasoconstric-
tor requirements), several studies report that ACE-
inhibitor use during surgery may also be associated
with increased risks of acute kidney injury and mor-
tality.5,6 However, despite these data, existing litera-
ture has not shown a consistent association between
ACE-inhibitor use and adverse postoperative out-
comes. For example, a propensity-matched cohort
study of 79,228 patients at the Cleveland Clinic found
no difference in hemodynamic characteristics, vaso-
pressor requirements, or cardiorespiratory complica-
tions among patients who were or were not using
ACE-inhibitors during noncardiac surgery.7 Further-
more, some research has also found that withdrawal
of ACE-inhibitors may itself lead to harm. For
instance, a contemporary study reported that with-
drawal of ACE-inhibitor therapy in patients under-
going coronary artery bypass was associated with
increased in-hospital cardiovascular events.8 Given
this uncertainty, it is not surprising that management
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of ACE-inhibitors in the perioperative period remains
a subject of ongoing controversy with clinical reviews
often recommending consideration of the risks and
benefits associated with use of these agents.9
It is important to note that driver of this ambiguity is
the very design of relevant studies. For instance, studies
that focus on patients undergoing coronary artery
bypass grafting surgery have limited external validity,
as these patients are very different from those who
undergo elective hip or knee replacement (such as those
included by Nielsen and colleagues). Additionally,
many studies suffer from methodological constraints or
biases. For instance, retrospective observational studies
often suffer from selection bias and residual confound-
ing; that is, the individuals chosen for inclusion in the
study and the variables available for analysis are often
limited by available data, curtailing the conclusions
that can be generated. Although the use of multivari-
able regression or propensity score techniques helps
address these limitations, residual confounding by
unmeasured variables always remains a threat to statis-
tical inference. The potential influence for this bias is
particularly relevant when examining the results of the
study by Nielsen and colleagues. Another important
limitation is survivor bias, a problem inherent in the
study by Mudumbai and colleagues. Put simply, for a
patient to resume ACE-inhibitors after surgery, this
same patient, must also survive for at least 15 to 30
days after surgery. Thus, for some patients, failure to
resume this treatment may simply be a marker of early
mortality rather than failure to resume the ACE itself.
The potential influence of this bias is supported by an
included sensitivity analysis, where a large change in
the adjusted OR was observed when patients suffering
early mortality were excluded. This swing in effect size
suggests that biases related to comparing patients who
survived to those who did not with respect to ACE use
may, in part, account for the results of the study.
These limitations aside, the studies brought forth by
both authors help inform practice with respect to the
use of these agents during surgery. In this context, 3
paradigms are relevant for practicing hospitalists.
First, if a patient is maintained on an ACE-inhibitor
before surgery, should the medication be temporarily
held before surgery to minimize hypotension during
anesthesia? The study by Nielsen and colleagues (com-
paring those on ACE-inhibitor treatment to those
without), in addition to the evidence generated from
other studies in this area10–12 suggest that this is a
rational decision. Although the existence of a
“withdrawal” state from abrupt cessation of ACE-
inhibitor use is theoretically plausible, this has yet to
be reliably reported in the literature. Given the short
half-life of most ACE-inhibitors, cessation 24 hours
before surgery appears to be the most pragmatic clini-
cal approach.
Second, if a patient is on an ACE-inhibitor before
surgery, when should the medication be resumed after
surgery? The findings from the study by Mudumbai
and colleagues, in addition to contemporary evi-
dence,7,8,13 support the resumption of these agents as
soon as possible following operative intervention.
Once hemodynamic stability and volume status have
been assured, risks associated with postoperative
ACE-inhibitor use appear to be outweighed by bene-
fits, though specific care is likely necessary in those
with preexisting renal dysfunction.14 A program that
ensures reconciliation of medications in the postopera-
tive setting may be valuable in ensuring that such
treatment is restarted.
Third, if a patient is not on ACE-inhibitor therapy,
should this be started before surgery for perioperative
or long-term benefit? Although neither study examines
this issue, the potential for significant risk make this
an unattractive option. Future interventional studies
with thoughtfully weighed safety parameters may be
necessary to assess whether such a paradigm may be
valuable.
The studies included in this issue of the Journal of
Hospital Medicine suggest that the use of ACE-inhibi-
tors during the perioperative period may be consid-
ered a function of time and place. Resuming ACE-
inhibitors and cessation of treatment at specific inter-
vals in relation to surgery can help ensure positive
outcomes. Hospitalists have an important role in this
regard, as they are ideally situated to manage these
agents in the many patients undergoing surgery across
the United States.
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